EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons names below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D,...Joint Filing Agreement • April 23rd, 2004 • Peizer Terren S • Services-misc health & allied services, nec
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons names below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D, including amendments thereto, with regard to the securities of Hythiam, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings.
COMMON STOCK PURCHASE WARRANT CATASYS, INC.Peizer Terren S • May 11th, 2021 • Services-misc health & allied services, nec • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ACUITAS GROUP HOLDINGS, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Catasys, Inc., a Delaware corporation (the “Company”), up to 294,118 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 11th, 2021 • Peizer Terren S • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June 10, 2021 by and between BioVie Inc., a Nevada corporation (the “Company”), and Acuitas Group Holdings, LLC, a California limited liability company (“Acuitas”). The Company and Acuitas are sometimes collectively referred to herein as the “Parties” and each is sometimes referred to herein as a “Party.”
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • May 10th, 2021 • Peizer Terren S • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this “Amendment”) is made and entered into as of May 9, 2021 by and among BioVie Inc., a Nevada corporation (“Buyer”), NeurMedix, Inc., a Delaware corporation (“Seller”), and Acuitas Group Holdings, LLC, a California limited liability company (“Guarantor”), solely for purposes of Section 10.16 of the Agreement (as defined below). Buyer, Seller and the Guarantor may be referred to herein, collectively, as the “Parties” and, individually, as a “Party.”
ASSET PURCHASE AGREEMENT by and among BioVie Inc., as Buyer, NeurMedix, Inc., as Seller, and Acuitas Group Holdings, LLC, as Guarantor Dated as of April 27, 2021Asset Purchase Agreement • April 27th, 2021 • Peizer Terren S • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 27, 2021, by and among BioVie Inc., a Nevada corporation (“Buyer”), NeurMedix, Inc., a Delaware corporation (“Seller”), and Acuitas Group Holdings, LLC, a California limited liability company (“Guarantor”), solely for purposes of Section 10.16. Buyer, Seller and the Guarantor may be referred to herein, collectively, as the “Parties” and, individually, as a “Party.”
Rule 10b5-1 Sales PlanPeizer Terren S • May 11th, 2021 • Services-misc health & allied services, nec
This Rule 10b5-1 Sales Plan is entered into on May 10th, 2021 (this “Sales Plan”) between Acuitas Group Holdings, LLC (“Seller”) and Jefferies LLC (“Broker”), acting as agent for Seller.
PURCHASE AND SALE AGREEMENTPurchase and Sale Agreement • February 4th, 2021 • Peizer Terren S • Services-computer processing & data preparation • Delaware
This Purchase and Sale Agreement (this “Agreement”), dated as of February 3, 2021 (the “Effective Date”), is entered into between Acuitas Group Holdings, LLC, a California limited liability company (“Acuitas”), and Crede Capital Group, LLC, a Delaware limited liability company (“Crede”), on the one hand, and X, LLC a Delaware limited liability company (“XLLC”), on the other hand, and solely for purposes of Section 5.01, Ramy El-Batrawi, an individual (“RE”). For the purposes of this Agreement, Crede, XLLC and RE are sometimes collectively referred to as the “Parties” and each separately referred to as a “Party”.
SETTLEMENT AGREEMENT AND MUTUAL RELEASESettlement Agreement and Mutual Release • February 4th, 2021 • Peizer Terren S • Services-computer processing & data preparation • California
This Settlement Agreement and Mutual Release ("Agreement") is entered into as of October 28th, 2019 (the "Effective Date"), by and between Ramy El- Batrawi, an individual, and X, LLC (collectively, "XLLC") on the one hand, and Terren Peizer, an individual, and Acuitas Group Holdings, LLC (collectively, "Acuitas") on the other hand, with reference to the following facts:
June 10, 2021 VIA EMAIL BioVie Inc.Asset Purchase Agreement • June 11th, 2021 • Peizer Terren S • Pharmaceutical preparations
JOINT FILING AGREEMENTJoint Filing Agreement • February 4th, 2021 • Peizer Terren S • Services-computer processing & data preparation
The undersigned acknowledge and agree that the foregoing statement on Schedule 13D (the “Statement”) is filed on behalf of each of the undersigned with respect to the beneficial ownership by the undersigned of the shares of common stock, $0.000001 par value per share, of Rideshare Rental, Inc., a Delaware corporation (the “Company”), and such other securities of the Company that the undersigned may acquire or dispose of from time to time, and that all subsequent amendments to this Statement may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. This agreement is being filed on behalf of each of the undersigned in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
